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Background: Hyperphosphatemia, may contribute to vascular calcification, and arteriosclerotic outcomes. Niacin administration can reduce serum 
phosphorus [P] concentrations in markedly hyperphosphatemic patients with end-stage renal disease. We examined the hypophosphatemic effect of 
extended-release niacin [ERN] in a population with normal to mildly impaired renal function, and without marked hyperphosphatemia. 
Methods and Results: Serum P concentrations were determined serially (at 0, 4,8,12,18,and 24 weeks) in 1547 dyslipidemic patients 
randomized in a 3:2:1 ratio to treatment with ERN (1g/d for 4 weeks, advanced to 2g/d for 20 weeks) combined with the selective prostaglandin 
receptor inhibitor laropiprant [L] (n=761), ERN alone (n=518), or placebo [PBO] (n=268). Repeated measures analysis revealed that ERN-L 
treatment resulted in a mean (with 95% confidence interval) serum P change of -0.35 (-0.39, -0.32) mg/dl. The net mean change in serum P 
concentrations, comparing ERN-L to PBO treatment (the latter caused a mean 0.06 mg/dl increase in serum P) was -0.41 (-0.46, -0.37) mg/dl. 
These results were consistent across the subgroups defined by estimated glomerular filtration rate [eGFR] being < 60 or ≥ 60 ml/min per 1.73 m2, 
a serum P of 3.5 mg/dl vs. < 3.5 mg/dl, the presence of clinical diabetes, or concomitant statin use.
Conclusions: ERN-L treatment causes a sustained ~0.4 mg/dl reduction in serum P concentrations, ~ 10% from baseline, which is unaffected 
by eGFR being < 60 or ≥ 60 ml/min per 1.73 m2. Our results suggest that an ERN treatment arm deserves the serious consideration for any future 
clinical trials testing the hypothesis that serum P-lowering may reduce cardiovascular disease outcomes in early chronic kidney disease patients. The 
improved tolerability of ERN-L offers a convenient way of treating patients with ERN.
